Drugs / ZX-7101A
last change Jan 2026 re-read 2 minutes ago

ZX-7101A

Developed for
influenza · viral respiratory tract infection
Investigated by
Nanjing Zenshine Pharmaceuticals

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT06841926 Feb → Apr 2025 viral respiratory tract infection Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 1 NCT06057103 Aug → Dec 2023 Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 1 NCT05955027 Jul → Aug 2023 influenza Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 1 NCT05949385 Jul → Sep 2023 Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 1 NCT05711797 Apr 2023 → Feb 2024 influenza Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 1 NCT05720091 Feb → Mar 2023 influenza Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 1 NCT05217732 Dec 2021 → Aug 2022 Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05702489 Jul 2022 → May 2023 influenza Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 33 trials
Phase 3 NCT07095257 Oct 2025 → Jan 2026 viral respiratory tract infection Nanjing Zenshine Pharmaceuticals Completed No outcome recorded
Phase 3 NCT06669351 Oct 2024 → Jul 2025 viral respiratory tract infection Nanjing Zenshine Pharmaceuticals Terminated No outcome recorded
Phase 3 NCT06099873 Nov 2023 → Feb 2025 viral respiratory tract infection Nanjing Zenshine Pharmaceuticals Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as ZX-7101A ClinicalTrials.gov intervention name — accepted as the source's own label NCT06099873
10

NCT05949385

NCT05955027

NCT05702489

NCT05711797

NCT06841926

NCT06057103

NCT05720091

NCT06669351

NCT07095257

NCT05217732

Route Oral “Administered as a selected, single oral dose of ZX-7101A in fasting state and non-fasting (with food) state.” NCT05217732